Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug duo shows promise against Tough-to-Treat liver cancer

NCT ID NCT04567615

Completed Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

Summary

This study tested a new combination of two immunotherapy drugs (relatlimab and nivolumab) for people with advanced liver cancer that had worsened after standard pill-based treatments. The main goal was to see if the drug combo could shrink tumors and control the cancer. Researchers measured how many people responded, how long the response lasted, and monitored side effects in 266 participants.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Local Institution - 0001

    Singapore, Central Singapore, 168583, Singapore

  • Local Institution - 0003

    Auckland, 1023, New Zealand

  • Local Institution - 0004

    Singapore, 308433, Singapore

  • Local Institution - 0009

    Mysowice, 41-400, Poland

  • Local Institution - 0010

    Ciudad de Buenos Aires, Buenos Aires, 1181, Argentina

  • Local Institution - 0011

    Seoul, Seoul-teukbyeolsi, 05505, South Korea

  • Local Institution - 0012

    Bytom, 41-900, Poland

  • Local Institution - 0013

    Krakow, Lesser Poland Voivodeship, 31-501, Poland

  • Local Institution - 0015

    São Paulo, São Paulo, 01246-000, Brazil

  • Local Institution - 0016

    Barretos, São Paulo, 14784400, Brazil

  • Local Institution - 0017

    Rosario, Santa Fe Province, S2002KDS, Argentina

  • Local Institution - 0018

    Santiago, Santiago Metropolitan, 8420383, Chile

  • Local Institution - 0019

    Buenos Aires, Distrito Federal, C1096AAS, Argentina

  • Local Institution - 0020

    Seongnam-si, 13496, South Korea

  • Local Institution - 0024

    Temuco, Región de la Araucanía, 4800827, Chile

  • Local Institution - 0025

    Belo Horizonte, Minas Gerais, 30130-090, Brazil

  • Local Institution - 0029

    Santiago, Santiago Metropolitan, 000000, Chile

  • Local Institution - 0031

    Taipei, 100, Taiwan

  • Local Institution - 0032

    Taoyuan District, 333, Taiwan

  • Local Institution - 0034

    Tainan, 704, Taiwan

  • Local Institution - 0036

    Cluj-Napoca, 400015, Romania

  • Local Institution - 0037

    Bucharest, 022328, Romania

  • Local Institution - 0038

    Craiova, Dolj, 200542, Romania

  • Local Institution - 0039

    Warsaw, 02-034, Poland

  • Local Institution - 0041

    Taichung, 40447, Taiwan

  • Local Institution - 0042

    Taipei, 11217, Taiwan

  • Local Institution - 0043

    Seoul, 06351, South Korea

  • Local Institution - 0045

    Ōsaka-sayama, Osaka, 589-8511, Japan

  • Local Institution - 0046

    Prague, 140 59, Czechia

  • Local Institution - 0047

    Hradec Králové, 50005, Czechia

  • Local Institution - 0048

    Brno, 65653, Czechia

  • Local Institution - 0049

    Madrid, 28041, Spain

  • Local Institution - 0050

    Donostia / San Sebastian, Gipuzkoa, 20014, Spain

  • Local Institution - 0051

    Madrid, 28009, Spain

  • Local Institution - 0054

    Yokohama, Kanagawa, 232-0024, Japan

  • Local Institution - 0058

    Pamplona, 31008, Spain

  • Local Institution - 0060

    Porto Alegre, Rio Grande do Sul, 91350-200, Brazil

  • Local Institution - 0063

    San Miguel de Tucumán, Tucumán Province, 4000, Argentina

  • Local Institution - 0066

    Barcelona, 08036, Spain

  • Local Institution - 0067

    Pessac, 33600, France

  • Local Institution - 0068

    Clichy, 92110, France

  • Local Institution - 0069

    Vandœuvre-lès-Nancy, Meurthe-et-Moselle, 54511, France

  • Local Institution - 0070

    Suceava, 720214, Romania

  • Local Institution - 0071

    Kyoto, 602-8566, Japan

  • Local Institution - 0072

    Matsuyama, Ehime, 790-0024, Japan

  • Local Institution - 0073

    Córdoba, 14004, Spain

  • Local Institution - 0074

    Lyon, 69004, France

  • Local Institution - 0075

    Ishikawa, 920-8641, Japan

  • Local Institution - 0076

    Yokohama, Kanagawa, 241-8515, Japan

  • Local Institution - 0077

    Hksar, 0, Hong Kong

  • Local Institution - 0079

    Shatin, 0, Hong Kong

  • Local Institution - 0089

    Ankara, 06230, Turkey (Türkiye)

  • Local Institution - 0090

    Edirne, 22030, Turkey (Türkiye)

  • Local Institution - 0091

    Kadiköy/Istanbul, 41380, Turkey (Türkiye)

  • Local Institution - 0100

    Cuauhtémoc, 06700, Mexico

  • Local Institution - 0101

    San Luis Potosí City, San Luis Potosí, 78250, Mexico

  • Local Institution - 0105

    Grenoble, 38043, France

  • Local Institution - 0106

    Oaxaca City, 68020, Mexico

  • Local Institution - 0107

    Shanghai, Shanghai Municipality, 200032, China

  • Local Institution - 0108

    Xi'an, Shan3xi, 710126, China

  • Local Institution - 0113

    Harbin, Heilongjiang, 150081, China

  • Local Institution - 0114

    Changsha, Hunan, 410013, China

  • Local Institution - 0117

    Hangzhou, Zhejiang, 310016, China

  • Local Institution - 0118

    Xi'an, Shaanxi, 710061, China

  • Unidade de Pesquisa Clínica do Hospital da Clínicas de Ribeirão Preto-Clinical Oncology

    Ribeirão Preto, São Paulo, 14051-140, Brazil

Conditions

Explore the condition pages connected to this study.

HEPATOCELLULAR CARCINOMA HEPATOMA LIVER CANCER, ADULT LIVER CELL CARCINOMA LIVER CELL CARCINOMA, ADULT